Latest in Highlight
New system enables pharmaceutical producers to export drugs before registering them with EDA
For the first seven months (7M) of 2020, total sales grew marginally by 0.04% y-o-y, amounting to EGP 43.8bn.
Every EGP 1 injected into The Sovereign Fund of Egypt brings 10-fold from investors
Companies’ representatives praise MIIC, Ministry of Health’ efforts to remove any obstacles
Tamer Essam, the deputy Egyptian Health Minister, along with the Indian Ambassador to Egypt, Rahul Kulshreshth, and representatives from the Pharmaceutical Export Promotion Council of India (Pharmexcil) inaugurated the Indian pavilion at the Pharmaconex 2019 edition. The exhibition is held at the Egypt International Exhibition Center (EIEC) from 6-8 April. A delegation of Pharmexcil, comprising …
Takeda Pharmaceutical Company held two meetings for scientific exchange and sharing experiences in relation to Hodgkin Lymphoma.
Egypt will be major manufacturing, marketing hub for his company’s products at regional, continental levels, says Saraya president
The new drug’s cure rate is 98%, and treatment period is two months: company’s director in Africa
Kazakhstan to support Egypt in negotiations to establish a free trade zone between Egypt and EAEU, establish joint projects
The ministry aims to benefit from the success of military cooperation with France to launch joint civil projects, especially in the electronics sector, says Al-Assar
FEDCOC against the decision, will file grievance against CAPA
The flotation of the Egyptian pound will play an influential role in determining the attractiveness of shares for investors during 2017, especially after the price of the US dollar increased to more than EGP 19, which will affect companies’ activities and their ability to make a profit. Financial and technical analysts expect that the most …
The increases will be 50% on medications priced less than EGP 50, 40% on the ones less than EGP 100, and 30% on the ones priced more than EGP 100 every six months
Companies demand government’s support in wake of higher production costs after pound’s flotation
German pharmaceutical giant Bayer has reported strong earnings and sales for the third quarter on higher demand for prescription drugs.
The German pharmaceutical giant has sweetened its buyout deal for Monsanto, which turned down an earlier offer. Bayer has added three dollars more per share, and it has its cash ready if the massive deal is accepted.
These drugs are highly effective as they inhibit cholesterol in the liver.
Around 170,000 doses of Hepatitis C medicine will be available for Egyptian patients late September
Novartis’s vice-president also called for the Ministry of Health to formulate a clear system to guarantee the delivery of modern and innovative drugs as quickly as possible and at the appropriate prices.
Lebanese authorities would now begin giving high priority to Egyptian products entering the Lebanese market.